Omilancor (BT-11) is an orally active lanthionine synthetase C-like 2 (LANCL2) binding compound for treating inflammatory bowel disease (IBD) (Kd value of 7.7 ?M).
In vitro measurement of cAMP in mouse splenocytes extracted from either WT or LANCL2?/? mice and treated with increasing doses of BT-11 demonstrates BT-11 stimulates cAMP production by activating the LANCL2 pathway[1].
Oral treatment with BT-11 (8 mg/kg/day) ameliorates colitis in mice. Safety assessment in rats indicateds that Oral treatment with BT-11 at high doses has an excellent safety profile up to 1000 mg/kg/day. In a dextran sodium sulfate colitis mouse model, oral administration of BT-11 upregulates the expression of IL-10 and downregulates the expression of TNF-α mRNA. It also upregulates LANCL2 expression in the gastrointestinal tract[1].
[1] Carbo A, et al. J Med Chem. 2016, 59(22):10113-10126.
















